Cost the baseline before enrollment: the annual study-management fee standalone sites quietly absorb

Most standalone sites do not lose money on a trial because the per-visit rate was slightly low. They lose money because the fixed cost of keeping that trial open, compliant, and ready was never priced at all. Regulatory maintenance, pharmacy oversight, storage, software subscriptions, and recurring training continue whether a participant walks through the door this month or not. If you fold those costs into overhead and hope to recover them visit by visit, a low-visit study will never pay for the infrastructure it depends on. The fix is simple to state and harder to practice: cost the baseline before enrollment, and present it as an annual study-management fee.

The visit math that quietly fails

Per-visit budgets create a comforting illusion. Each completed visit looks paid for, so the study looks covered. What the visit rate hides is everything that happens between visits, and everything that had to be in place before the first visit could happen at all.

A trial that enrolls slowly, pauses, or runs with long gaps between visits still requires the same upkeep. Files must stay current. Equipment must stay monitored. Staff must stay trained and available. Systems must stay licensed. None of that work arrives attached to a visit, so none of it gets recovered when the visit count disappoints.

Standalone sites are especially exposed. A network can spread fixed costs across many locations and studies. A single site carries the same categories of cost on a narrower base, and the silent subsidy compounds across every active trial on its books. The answer is not to inflate per-visit rates until the math somehow works. Inflated rates are easy for a sponsor or a contract research organization (CRO) to challenge, because they disconnect price from the work performed at the visit. The baseline deserves its own line, named for what it actually is.

What belongs in the baseline

Separate two kinds of cost that sites routinely blend together. Study-specific costs are screening procedures, participant visits, laboratory work, imaging, and investigator assessments tied to a protocol event. Baseline costs are the standing cost of running an active trial responsibly for a year. The baseline buckets, trial by trial, usually include:

• Regulatory maintenance. Keeping approvals, amendments, safety reports, and essential documents current, including institutional review board (IRB) continuing review, and keeping the electronic regulatory binder (eREG) audit-ready throughout the study, not just at closeout.
• Pharmacy oversight and temperature monitoring. Pharmacist and pharmacy staff time not tied to a single dispensing event, plus continuous monitoring, documentation, and excursion follow-up for investigational product in storage.
• Kit storage and supplies handling. Receiving, inventorying, storing, and reconciling laboratory kits and study supplies, including the shelf space and staff attention they consume long before use.
• Systems subscriptions. The clinical trial management system (CTMS), electronic source (eSource), and eREG platforms a modern site runs on. These are priced to the organization, not to a visit, yet every active trial depends on them.
• Recurring training. Good Clinical Practice (GCP) refreshers, protocol retraining after amendments, and safety training that keeps a team qualified to run the study at any moment.
• Principal investigator (PI) and leadership oversight. Real time spent on oversight, quality review, and sponsor communication that no single visit payment was designed to cover.

None of these items is exotic. The discipline is not discovering the costs. It is writing them down, per trial, before the budget conversation begins.

A benchmark shared in the community

I was prompted to write this after a benchmarking exchange among site operators in a professional community I take part in. One peer site operator shared experience from tracking site costs for 17 years. Two points from that shared benchmarking experience are worth passing on, with the right attribution: they are not my site's figures, and they are not an industry standard.

First, that operator found that overhead at a standalone site runs at least 30 percent higher than at network sites, because the network spreads the baseline across a larger structure. Second, that tracking put the annual baseline at around $29k per trial, before study-specific work is counted.

Use those figures as a reasonableness check, not as your number. If your own costing lands nowhere near that range, ask whether whole categories are still hiding inside general overhead. Your baseline must come from your ledgers, your subscriptions, and your staff time. The community benchmark simply proves the exercise is worth doing honestly.

The method: cost it trial by trial

First, list the buckets for one active trial. Write down what each category above costs your site over a full year of keeping that trial open. Use real invoices for subscriptions, real salary time for oversight and maintenance, and real monitoring and storage costs. Note which costs are shared across trials, and how many trials share them.

Second, divide honestly. Allocate shared costs across the trials that actually use them, using a method you can explain in one plain sentence. Do not load a shared system entirely onto one study. A fee you can defend line by line is a fee you can hold under pressure.

Third, total the baseline for that trial, for one year. That total is your annual study-management fee. It is not a startup fee, which covers the one-time work of opening a study, and it is not an archiving fee, which covers the end of one. It is the recurring price of keeping the study alive and compliant, and it should recur for each year the study remains active.

Fourth, write the assumptions down. Which buckets are included, how shared costs were divided, and what happens if the study extends, pauses, or expands. Clear assumptions protect both sides when scope changes.

Separate the baseline from study-specific costs

Clean separation is what makes this fee credible. The annual study-management fee covers the standing baseline and nothing else. Study-specific work — visits, procedures, participant stipends, and protocol-driven testing — stays in the per-visit and pass-through sections of the budget, priced on its own merits.

That separation helps the sponsor as much as the site. When the two are blended, neither side can tell which part of the budget is failing when a study slows down. When they are separate, a slow-enrolling study still funds its own upkeep, a high-visit study is not overcharged on visits to compensate, and both sides can renegotiate the correct line when the protocol changes instead of reopening the entire budget.

How to present the fee at budget negotiation

Present the fee early, in writing, as a named line item: annual study-management fee. Attach the bucket list and the allocation method. Keep the presentation factual and brief. You are not asking for a favor or apologizing for your cost structure. You are showing the sponsor what it costs to keep their study open, compliant, and ready at your site for a year.

Expect questions, and welcome them. A sponsor who asks which systems the fee covers, or how pharmacy oversight time was estimated, is engaging with a real cost model. If a sponsor declines the fee entirely, that is information too: the study, as budgeted, expects your site to absorb its baseline, and you can decide — before enrollment, not after — whether your site can afford to run it.

The point

Standalone sites are not fragile versions of networks. We are independent businesses that carry our own infrastructure, and that independence is part of what sponsors value: direct accountability, stable teams, and a principal investigator who knows the study. At Amavita Research Services, our Miami cardiovascular trial site, we care for more than 18,000 active cardiology patients and operate with zero United States Food and Drug Administration (FDA) Form 483 findings. That record exists because the baseline work gets done every week, whether or not it appears on a visit invoice.

Cost that work. Name it. Present it as the annual study-management fee it is, separate from every study-specific cost. Sites that price the baseline before enrollment stop quietly absorbing it — and studies get budgets built on what trials actually cost to run.

Julio G. Martinez-Clark is CEO of Amavita Research Services, a Miami cardiovascular trial site, and CEO of bioaccess, a first-in-human CRO.